PTC Therapeutics Q4 revenue falls to $164.7M; full-year net income $682.6M
PTC Therapeutics reported fourth-quarter 2025 total revenue of $164.7 million, down from $213.2 million a year earlier, and a net loss of $135.0 million, wider than the $65.9 million loss in the prior-year quarter. For the full year, total revenue rose to $1,730.7 million and net income was $682.6 million, but both figures were lifted by a $998.4 million Novartis votoplam collaboration and license revenue item. The company also issued 2026 total product revenue guidance of $700 million to $800 million.
Key points
- Q4 2025 total revenue was $164.7 million versus $213.2 million in Q4 2024; Q4 net loss was $135.0 million versus $65.9 million.
- Q4 results include a $98.6 million change in the Translarna France sales allowance estimate, a life-to-date adjustment.
- Full-year 2025 net income was $682.6 million, or $7.78 per diluted share, versus a net loss of $363.3 million in 2024.
- 2026 guidance: total product revenue of $700 million to $800 million, with the majority expected from Sephience.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 19, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.